Roche Reviewing Next Steps For Lebrikizumab After Mixed Phase III Data

One of two identical Phase III trials testing the IL-13 blocker in severe asthma patients met its primary endpoint, while the other failed.

The fate of Roche’s late-stage respiratory drug lebrikizumab appears uncertain after mixed results in Phase III testing. The company announced Feb. 29 that only one of two identical studies testing the interleukin-13 blocker in patients with severe asthma turned in positive results while the other failed.

The news is a disappointment for Roche, which has been looking to bolster its portfolio in a competitive market for...